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Abstract Huntington’s disease (HD) is a dominant neu-
rodegenerative disorder that is due to expansion of an
unstable HTT CAG repeat for which genome-wide genetic
scans are now revealing chromosome regions that contain
disease-modifying genes. We have explored a novel
human–mouse cross-species functional prioritisation
approach, by evaluating the HD modifier 6q23–24 linkage
interval. This unbiased strategy employs C57BL/6J (B6J)
HdhQ111 knock-in mice, replicates of the HD mutation, and
the C57BL/6J-chr10A/J/NaJ chromosome substitution strain
(CSS10), in which only chromosome 10 (chr10), in synteny
with the human 6q23–24 region, is derived from the A/J
(AJ) strain. Crosses were performed to assess the possi-
bility of dominantly acting chr10 AJ-B6J variants of strong
effect that may modulate CAG-dependent HdhQ111/? phe-
notypes. Testing of F1 progeny confirmed that a single AJ
chromosome had a significant effect on the rate of body
weight gain and in HdhQ111 mice the AJ chromosome was
associated subtle alterations in somatic CAG instability in
the liver and the formation of intra-nuclear inclusions, as
well as DARPP-32 levels, in the striatum. These findings in
relatively small cohorts are suggestive of dominant chr10
AJ-B6 variants that may modify effects of the CAG
expansion, and encourage a larger study with CSS10 and
sub-strains. This cross-species approach may therefore be
suited to functional in vivo prioritisation of genomic
regions harbouring genes that can modify the early effects
of the HD mutation.
Introduction
Huntington’s disease (HD) is a dominantly inherited neu-
rodegenerative disorder, usually of adult onset, character-
ised by involuntary choreic movements, cognitive
impairment and behavioural changes. It is caused by the
expansion of an unstable polymorphic CAG repeat in HTT
(previously HD) (The Huntington’s Disease Collaborative
Research Group 1993). The expanded CAG repeat is the
major determinant of age at onset of motor symptoms, such
that the longer the repeat the earlier the onset. It explains
about 50–70 % of the variance in motor age at onset
(Andrew et al. 1993; Duyao et al. 1993; Snell et al. 1993),
while the remainder of the variance is highly heritable
strongly implying the existence of genetic factors that
Electronic supplementary material The online version of this
article (doi:10.1007/s00335-014-9552-9) contains supplementary
material, which is available to authorized users.
E. M. Ramos  M. Kovalenko  J. R. Guide  J. St. Claire 
T. Gillis  J. S. Mysore  V. C. Wheeler  M. E. MacDonald (&)
Center for Human Genetic Research, Massachusetts General
Hospital, Boston, MA 02114, USA
e-mail: macdonam@helix.mgh.harvard.edu
E. M. Ramos  J. Sequeiros  I. Alonso
UnIGENe, Institute for Molecular and Cell Biology (IBMC),
University of Porto, 4150-180 Porto, Portugal
J. Sequeiros  I. Alonso
CGPP, Institute for Molecular and Cell Biology (IBMC),
University of Porto, 4150-180 Porto, Portugal
J. Sequeiros  I. Alonso
Instituto de Cieˆncias Biome´dicas Abel Salazar (ICBAS),
University of Porto, 4050-313 Porto, Portugal
M. E. MacDonald
Center for Human Genetic Research, Massachusetts General
Hospital, Simches Research Building, Room 5414,
185 Cambridge Street, Boston, MA 02114, USA
123
Mamm Genome (2015) 26:119–130
DOI 10.1007/s00335-014-9552-9
modulate the rate of the pathogenic process that leads to
onset of symptoms (Djousse et al. 2004; Gusella and
MacDonald 2009; Wexler et al. 2004).
Amongst other potential modifier loci identified in
genome wide linkage scans (Gayan et al. 2008), a scan
using affected HD sibling pairs, the HD-MAPS study, has
provided strong evidence for a quantitative trait locus
(QTL) at the 6q23–24 modifying residual age of onset of
neurological symptoms (Li et al. 2003, 2006). This
6q23–24 interval contains at least 80 genes, making it
challenging to identify the gene (or genes) with the func-
tional variant(s) that actually modify onset. Furthermore,
unbiased linkage and association studies are gaining
momentum and undoubtedly will identify many more
genomic regions. These can be dissected with follow-up
genetic and genomic studies with additional subjects and
the recent advent of highly efficient gene targeting tech-
niques now permit studies of candidate gene variants in
human HD cells. However, efficacy in modulating the HTT
CAG-initiated disease process and its outcomes in vivo
may be needed to reveal modifier effects at each of many
implicated modifier loci across the genome but is imprac-
tical on a gene-by-gene basis.
Therefore, we have explored an unbiased cross-species
genetic approach to the problem of prioritising and homing
in on HD modifier genes that utilises a mouse resource that
has proven to be a powerful route to identification and
validation of QTLs: the chromosome substitution mouse
strains (CSSs). These mice, commonly referred as CSSi,
carry both copies of a chromosome i from a donor strain,
e.g. A/J (AJ), while all other chromosomes from the host
strain, e.g. C57BL/6J (B6J), are intact and homozygous
(Nadeau et al. 2000). By testing mice from a CSS strain for
a phenotype of interest, it can be immediately inferred that
phenotypic differences between the CSS and the host strain
are due to at least one QTL resident on the substituted
chromosome. The same principle can be used to identify
regions carrying potential genetic modifiers whose effects
may only be revealed in the presence of the primary
mutation that is necessary to produce the phenotype that is
modulated. The cross between CSSs mice and mice car-
rying a CAG expansion allele that precisely replicates the
HD mutation, such as HdhQ111 knock-in mice (Wheeler
et al. 1999; White et al. 1997), could therefore provide an
unbiased route to prioritise and validate in vivo the initially
large genomic regions that harbour HD modifier loci. The
HdhQ111 knock-in mice exhibit accurate expression of
mutant huntingtin from CAG repeats inserted into the
mouse HD gene homologue (Htt, formally Hdh) and het-
erozygous mutant mice display phenotypes at a young age
that are dominant, Htt CAG repeat length-dependent and
manifest in medium spiny neurons (MSNs) (Wheeler et al.
2000, 2002), conforming to the key genetic features of the
HD mutation. Theoretically, a difference in any of these
phenotypes between the F1 progeny and parental knock-in
mice implies that at least one or more genetic modifiers of
HD mutation-initiated disease process reside on the
substituted chromosome.
In this range-finding study, we have explored this
approach, by applying it to the human 6q23–24 region
implicated in harboring modifier(s) of HD onset. Since the
human chromosome 6 is in synteny with the mouse chro-
mosome 10 (chr10), we used a cross between CSS10 mice
and B6/J HdhQ111/? knock-in mice to generate progeny with
one copy of an AJ chr10 and heterozygous for the HD
mutation in an otherwise B6J background. Comparing these
F1 mice with B6/J HdhQ111/? knock-in mice tests if chr10
AJ-B6J genetic variants are of sufficient effect size to alter
early, dominant and CAG length-dependent phenotypes,
such as Htt CAG somatic instability (Lee et al. 2010, 2011;
Wheeler et al. 1999), intranuclear inclusions of mutant
huntingtin (Wheeler et al. 2002) and expression of dopa-
mine- and cAMP-regulated phosphoprotein, 32 kDa
(DARPP-32). Further motivating this comparison, HdhQ111
and other Htt CAG knock-in mice exhibit decreased body
weight, which on other genetic backgrounds appears to
manifest at old ages as a low penetrant phenotype (Holter
et al. 2013; Lin et al. 2001), while CSS10 mice carry chr10A/J
variants that moderate the rapid B6J weight gain associated
with an A/J obesity-resistance QTL at chr10 (Burrage et al.
2010; Singer et al. 2004). We hypothesised, therefore, that
rate of weight gain may provide an HD repeat relevant pri-
mary phenotype with which to calibrate our ability to detect
the functional effects of chr10 variants in our test cross.
Materials and methods
Mice
The C57BL/6J-Chr10A/J/NaJ (CSS10) mice that carry both
chr10 from strain AJ on an otherwise C57BL/6J (shortened
here to B6J) background (Nadeau et al. 2000) and wild type
B6J mice were obtained from The Jackson Laboratories
(Jackson Laboratories, Bar Harbor, ME). The congenic
HdhQ111 knock-in line of mice used in this study carry the
targeted Htt CAG expansion allele (Wheeler et al. 1999;
White et al. 1997) on the B6J background. The renaming of
the human HD gene, from HD to HTT, and of its murine
homologue, from Hdh to Htt, has obscured connexions to
previous research. Therefore, to maintain consistency with
the literature and with the names of the lines of mice
deposited in repositories, we use HdhQ111 to denote the
published name of the specific line of mice that we have
utilised. The locus name Htt is used to refer to the general
knock-in approach (e.g. Htt CAG knock-in) and to the
120 E. M. Ramos et al.: CSS assessment of HD modifier locus
123
precise size of the expanded CAG repeat allele, which varies
in any given progeny due to intergenerational CAG repeat
instability. Thus, the actual genotyped Htt CAG repeat size
of the parental HdhQ111 mice was 139 CAG repeats. As
shown in Fig. 1, crosses between HdhQ111 knock-in and wild
type (CSS10 and B6J) mice were made in one direction—
HdhQ111/? male 9 B6J and CSS10 females—in order to
control for possible parental effects of the Htt mutant allele.
Briefly, male heterozygous HdhQ111/? knock-in mice were
crossed with CSS10 female mice in order to generate wild
type Hdh?/?.C57BL/6J.Chr10A/J (Hdh?/?B6J.AJ10) and
mutant HdhQ111/?.C57BL/6J.Chr10A/J (HdhQ111/?B6J.AJ10)
mice that carried one chr10 from strain AJ on an otherwise
B6J background. Subsequently, the same male heterozygous
HdhQ111/? knock-in mice were crossed with B6J female
mice in order to generate wild type Hdh?/?.C57BL/6J
(Hdh?/?B6J) and mutant HdhQ111/?.C57BL/6J (HdhQ111/
?B6J) mice on a complete B6J background. Animal
experiments were performed to minimise pain and discom-
fort, under an approved protocol of the Massachusetts
General Hospital Subcommittee on Research Animal Care.
Experimental design
From the F1 offspring mice (n = 119), we selected two
different sets of mice for phenotypic somatic instability (set
1) and immunohistochemistry assays (set 2), with groups
consisting of both female and male, Htt mutant and wild
type mice from both B6J.AJ10 and B6J crosses (Supple-
mentary Table 1). Set 1 (n = 20) consisted of ten 5-month-
old Htt mutant mice per genotype (HdhQ111/?B6J.AJ10 and
HdhQ111/?B6J) matched by gender (5 female and 5 male
per genotype) and Htt CAG repeat size. Set 2 (n = 40)
consisted of ten 5-month-old mice per genotype (HdhQ111/
?B6J.AJ10, HdhQ111/?B6J, Hdh?/?B6J.AJ10 and Hdh?/
?B6J) matched by gender (5 females and 5 males per
genotype) and Htt CAG repeat size. All Htt mutant mice
used in this study were heterozygous for the Htt CAG
mutation. As we could not generate data for all the animals
in all assays, the number of mice included into the analyses
of each test is given in the legends.
Body weight
F1 offspring mice were fed Prolab Isopro RMH 3000 (PMI
Nutrition International, Brentwood, MO) ad libitum and
weighed at weekly intervals from the time of weaning
(3 weeks) until 5 months (*24 weeks). The following
body weight traits were analysed: initial (IW: weight in
grams at *25 days of age), medium (MW: weight in
grams at *98 days of age) and final weight (FW: weight at
*169 days of age). We also calculated the mean weight
gain/day in grams for the first (EWG) and last (FWG)
*72 days and the weight gain per day in grams/day (WG),
as previously described (Burrage et al. 2010).
Genotyping and analysis of somatic instability
Genomic DNA was isolated from fresh-frozen collected
tissues (tail, striatum and liver) using DNeasy Blood &
Tissue kit (Qiagen, Valencia, CA). Genotyping of the
HdhQ111 knock-in allele was carried out using a previously
established polymerase chain reaction (PCR) amplification
assay, with fluorescently labelled primers (Wheeler et al.
2003). The size of the PCR products was then determined
using the ABI PRISM 3730xl automated DNA Sequencer
(Applied Biosystems, Foster City, CA) and GeneMapper
version 3.7 software. All runs included the same control
DNAs of known Htt CAG repeat size. Somatic instability
was quantified from GeneMapper traces as described pre-
viously (Lee et al. 2010). Briefly, the main allele was
identified as the highest peak in each analysis and
peaks with height less than 20 % of the main allele were
excluded. The peak height of each peak was divided by the
Fig. 1 HdhQ111 knock-in mice with different chr10 genetic back-
grounds. Representative diagram of the breeding scheme showing the
manner in which both chr10—AJ or B6J—and Htt alleles—wild type
(?) or HdhQ111 knock-in allele (Q111)—were passed to the F1
progeny mice used in this study. The actual CAG size of the HdhQ111
knock-in allele in the paternal mice was 139 CAGs while in the F1
progeny ranged from 133 to 149 CAGs
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sum of the heights of all signal peaks and then multiplied
by the CAG change relative to the main allele. These
values were summed to generate an instability index. To
qualitatively assess the different patterns of repeat insta-
bility in liver and striatum, the distance (in CAG repeats)
between the two modes and the distance (in CAG repeats)
between the constitutive repeat mode and the longest repeat
was calculated as previously described (Lee et al. 2011).
Immunohistochemistry
Coronal sections of paraformaldehyde-perfused and post-
fixed, gelatin-embedded hemisphere brains were performed
at Neurosciences Associates (NSALabs, Knoxville, TN)
using MultiBrain Technology. With this technology, all
mouse brain hemispheres were embedded in one single
block that was freeze-sectioned at 35 lm in the coronal
plane (throughout the striatum) with a sliding microtome,
resulting in free-floating sections. Designated sections across
the striatum were stained with either EM48 and thionine
counterstain or DARPP-32 at 210-lm intervals. Bright field
microscopy was performed with an Olympus BX51 micro-
scope equipped with a Qcolor5 Olympus camera and
Qcapture image acquisition software. Images that were to be
quantified and compared were taken with the same exposure
times. For the EM48 sections, three micrographs (940
objective) were taken from the dorsal medial striatum in
three consecutive sections from each mouse. The number of
nuclear huntingtin inclusions was quantified in three striatal
areas per mouse and normalised to the number of EM48-
positive cells. For the DARPP-32 sections, micrographs (94
objective) in three consecutive sections were taken from
each mouse and DARPP-32 intensity was quantified using
ImageJ image analysis software (Schneider et al. 2012).
Statistical analyses
Pairwise comparisons were determined using an unpaired t test
or a nonparametric unpaired Mann–Whitney test (for data that
did not display a normal distribution). Statistical analyses were
performed using GraphPad Prism 6.00 (GraphPad Software, La
Jolla, CA). Sample size estimation (power = 0.80, a = 0.05)
was calculated using the R package samplesize (http://CRAN.
R-project.org/package=samplesize).
Results
Genetic variance between B6J and AJ strains at mouse
chr10
A genome wide HD modifier linkage scan has provided
strong evidence for a QTL, between markers D6S1009 and
D6S2436, at the human 6q23–24 interval, that modulates
age at HD neurological onset (Li et al. 2003, 2006). This
region (*16 Mbp) includes at least 80 different human
genes that corresponded to 72 homologue genes in the
mouse, as annotated in the Ensembl Genome Browser
(Flicek et al. 2013). The human 6q23–24 interval is in
synteny with part of mouse chr10 (Fig. 2a), comprising
71 of the homologue genes. According to the Mouse
Genome Informatics database (Eppig et al. 2012), B6J and
AJ mice have about 16,000 allelic differences at chr10
(*131 Mbp): 106 non-synonymous, 205 synonymous,
*14,600 intronic, 576 locus-region (in an untranscribed
region flanking a gene: 2 Kb 50 or 0.5 Kb 30), 316 mRNA-
UTR (in the transcript but not in the coding region interval)
and 3 splice-site (in the first or two last bases of an intron)
variants (Fig. 2b). From these variants, 19 coding non-
synonymous SNPs, most likely to have functional impact,
are located in 12 homologues of human genes located at
6q23–24: Mthfd1 l, 1700052N19Rik, Katna1, Sash1,
Samd5, Epm2a, Utrn, Stx11, Hivep2, Nhsl1, Tnfaip3 and
Ifngr1.
To determine whether allelic differences at any of these
genes or other loci across chr10 may strongly alter domi-
nant consequences of the expanded CAG repeat at the Htt
locus in heterozygous HdhQ111 mice, we bred the latter
with either CSS10 mice or with B6J mice as described in
‘‘Materials and methods.’’ For this range-finding study, the
cohorts of F1 progeny were phenotyped at about 5 months
of age by monitoring the rate of body weight gain, pre-
viously reported to be associated with B6J.AJ chr10 vari-
ants, and five outcomes of the HdhQ111 allele: somatic
CAG repeat instability in the striatum and in the liver (Lee
et al. 2010, 2011; Wheeler et al. 1999), the appearance of
diffuse nuclear huntingtin stain and intranuclear huntingtin
inclusions in medium size spiny striatal neurons (Wheeler
et al. 2002) and a novel phenotype, the decrease in
DARPP-32 levels in the striatum. At 5 months of age, the
majority of these CAG-dependent phenotypes were
expected from previous experience to be fully penetrant on
the B6J genetic background, minimising the number of
mice of each genotype to be evaluated. F1 cohorts of *ten
mice of each genotype (five males and five females) was
chosen as a reasonable starting point for assessing the
possibility of dominant variants of strong effect that would
become apparent with a subset of each cohort in each
assay.
Body weight
We examined the rate of body weight gain as a primary
endpoint because it has been reported, from phenotyping
across the members of the entire CSS panel, that dominant
AJ chr10 variants dampen the rapid rate of body weight
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gain of B6J mice, in F1 B6J.AJ10 mice (Burrage et al.
2010). Furthermore, in HD subjects weight loss is often
observed in the course of the disease (Aziz et al. 2008;
Djousse et al. 2002; Farrer and Yu 1985; Robbins et al.
2006; Sanberg et al. 1981) despite normal to very high
caloric intake (Marder et al. 2009; Morales et al. 1989;
Trejo et al. 2004). It is correlated with disease progression
(Myers et al. 1991) and patients with higher expanded
CAG repeat exhibit more rapid loss of body weight (Aziz
et al. 2008). In the knock-in HdhQ111 mice (on a CD1
background), homozygous males had a lower body weight
than wild type and heterozygous mice at 28 weeks (Me-
nalled et al. 2009). Therefore, to assess the potential effect
of the HdhQ111 mutation on a B6J background and of the
different test genetic backgrounds (chr10B6J/B6J vs
chr10B6J/AJ), we analyzed body weight at three different
ages (3, 14, and 24 weeks). As shown in Fig. 3, wild
type B6J mice showed significant lower body weight
than wild type B6J.AJ10 mice at 3 weeks of age for both
genders (p = 0.0008, mean IW ± SD: 10.02 ± 1.89 vs
13.03 ± 1.74 for females and p \ 0.0001, mean IW ± SD:
9.22 ± 1.72 vs 13.92 ± 2.29 for males). However, they
tended to gain more weight per day than B6J.AJ10 mice
(p = 0.0026, mean WG ± SD: 0.081 ± 0.013 vs 0.063 ±
0.012 for females and p = 0.0302, WG ± SD: 0.133 ±
0.014 vs 0.113 ± 0.024 for males), resulting in similar
body weights between B6J and B6J.AJ10 mice by week 24
(mean FW ± SD: 21.64 ± 1.35 vs 21.99 ± 0.64 for
females, and 28.35 ± 1.63 vs 30.13 ± 2.03 in males,
respectively). Therefore, the presence of the AJ10 chro-
mosome was associated with less rapid weight gain,
thereby confirming an earlier phenotypic effect on an
otherwise B6J background. However, there was no signif-
icant difference in weight at any time point between
HdhQ111 mutant and wild type mice, for either of the two
different chr10 genetic backgrounds.
CAG instability of HdhQ111 knock-in alleles
Previous studies have shown that in HdhQ111 knock-in mice
intergenerational CAG repeat length changes with a
paternal expansion bias (Lloret et al. 2006; Wheeler et al.
1999). In our study, the Htt mutant allele was transmitted
from male HdhQ111/? knock-in mice with the same back-
ground (B6J) and constitutional (i.e. in tail DNA) CAG
repeat length (139 CAG repeats). Therefore, as expected,
we observed a paternal expansion bias (74 % in crosses of
HdhQ111/? mice with B6J and 82 % in crosses with CSS10
mice), but no significant repeat length difference in the
transmissions of the Htt 139 CAG allele to HdhQ111/?B6J
(mean ± SD = 3.04 ± 3.18) and HdhQ111/?B6J.AJ10
mice (mean ± SD = 2.25 ± 2.77) was detected. Figure 4
Fig. 2 Genetic architecture of the *131 Mbp mouse chr10. a Rep-
resentative homology scheme of mouse chr10 compared with human.
b Location of the reported genetic variants between B6J and AJ
strains at mouse chr10. Coding non-synonymous variants are
represented in red, coding synonymous in dark blue, locus-region
in orange, mRNA-UTR in purple, splice-site in light blue and intronic
in grey (Color figure online)
E. M. Ramos et al.: CSS assessment of HD modifier locus 123
123
shows the actual CAG repeat size of the HdhQ111 knock-in
allele in both HdhQ111/?B6J and HdhQ111/?B6J.AJ10
progeny used in this study.
HdhQ111/? knock-in mice also exhibit CAG length, age
dependent and tissue specific somatic instability, with
significant accumulation of expansions in striatum and
liver that becomes apparent by 5 months of age (Lee et al.
2010, 2011; Wheeler et al. 1999). In order to evaluate the
potential effect of AJ-B6J genetic variants at chr10 in
somatic instability, we extracted genomic DNA from one
stable (tail) and two unstable (liver and striatum) tissues
from HdhQ111/?B6J and HdhQ111/?B6J.AJ10 mice at
5 months of age. As shown in Fig. 5a, the Htt CAG repeats
in tail were very stable in contrast to striatum and liver that
showed significant levels of instability, irrespective of
chr10 background. Next we quantified the levels of repeat
instability for each tissue using a conservative threshold
(20 % of the highest peak). As shown in Fig. 5b, the
highest instability indices were observed in the liver
(?11.95 ± 0.81 for HdhQ111/?B6J and ?12.71 ± 1.03
for HdhQ111/?B6J.AJ10) followed by the striatum
(?8.15 ± 1.51 for HdhQ111/?B6J and ?8.40 ± 1.27 for
HdhQ111/?B6J.AJ10). There was no significant difference
for the instability indices, or for the expansion and con-
traction indices (data not shown) when comparing the two
groups of HdhQ111 mice. As previously described (Lee
et al. 2011), the patterns of repeat instability differed
between liver and striatum: while in the liver a distinct
population of unstable CAG repeats was evident, in the
striatum these repeats were more broadly distributed. To
qualitatively characterise these different patterns of repeat
Fig. 3 One single copy of AJ chr10 has an effect on the patterns of
weight gain. Scatter plots represent the individual values of the initial
weight (at *3 weeks of age), the final weight (at *24 weeks of age)
and the mean weight gain per day for a female and b male mice. The
mice used for the body weight analysis are as follows: Hdh?/?B6J (13
females and 14 males), HdhQ111/?B6J (9 females and 16 males),
Hdh?/?B6J.AJ10 (10 females and 10 males) and HdhQ111/?B6J.AJ10
(15 females and 5 males). Line represents mean of values for each
genotype. ****p \ 0.0001, ***p \ 0.001, **p \ 0.01 and *p \ 0.05
Fig. 4 CAG repeat size of the knock-in alleles in HdhQ111/?B6J and
HdhQ111/?B6J.AJ10 progeny. The mean CAG repeat size of the mice
used in this study was 142.0 ± 3.2 for HdhQ111/?B6J (n = 27) and
141.3 ± 2.8 for HdhQ111/?B6J.AJ10 (n = 28). Solid line represents
mean of CAG repeat for each genotype while the dashed line
represents the CAG repeat size transmitted from the parental HdhQ111/
?B6J mice (139 CAGs)
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instability, two additional measurements were made: the
distance to the longest repeat (striatum and liver, Fig. 5c)
and the distance between the two modes (liver, Fig. 5d).
There was no significant difference in the patterns of repeat
instability when comparing HdhQ111/?B6J and HdhQ111/
?B6J.AJ10. However, as for the instability index, we did
observe a numerically larger distribution of the unstable
repeats in the liver of HdhQ111/?B6J.AJ10 mice.
Nuclear mutant huntingtin
Another early, dominant, CAG-length-dependent phenotype
in HdhQ111 mice is the time-dependent immunostaining of
mutant huntingtin in the nuclei of striatal neurons. Previous
studies have detected early (*2.5 months) diffuse-immuno-
staining nuclear mutant huntingtin and later (6–12 months)
intranuclear inclusions of mutant huntingtin amino-terminal
fragments, using the anti-huntingtin antibody EM48 (Lloret
et al. 2006; Wheeler et al. 2000, 2002). In order to determine
the effect of the chr10 background on the nuclear mutant
huntingtin phenotype, we immunostained striatal sections
from 5-month mice with EM48 antibody (Fig. 6a). As
expected, EM48 staining was not detected in the wild type
mice (Fig. 6a, right panel). When comparing Htt CAG knock-
in mice, we found a similar number of nuclei with diffuse
mutant huntingtin stain (data not shown) and some nuclei
Fig. 5 HdhQ111/?B6J.AJ10 mice showed a mild increase of liver
somatic repeat instability when compared to HdhQ111/?B6J mice.
a GeneMapper traces of PCR-amplified Htt CAG repeats from tail,
striatum and liver of representative 5 months HdhQ111/?B6J (144
CAGs) and HdhQ111/?B6J.AJ10 (141 CAGs) mice. b Somatic repeat
instability was quantified from GeneMapper traces by determining an
instability index for tail, striatum and liver of each mouse.
Additionally, to capture the different patterns of repeat instability in
liver and striatum, we measured c the distance between the
constitutive repeat mode and the longest repeat after background
correction and d the distance between the modes of the constitutive
and somatically expanded repeats. HdhQ111/?B6J (n = 8) mice are
represented in squares and HdhQ111/?B6J.AJ10 (n = 8) mice in
triangles
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exhibited intranuclear inclusions (Fig. 6a, left panel). We
found that, compared to HdhQ111/?B6J mice, the percentage
of EM48-positive nuclei with intranuclear inclusions was
higher in HdhQ111/?B6J.AJ10 mice (35.88 ± 11.45 vs
46.69 ± 12.11, respectively), although the difference did not
reach statistical significance (Fig. 6b; p = 0.0694). More-
over, the number of intranuclear inclusions was found to
depend on the constitutive CAG repeat length of HdhQ111/
?B6J.AJ10 mice, with longer CAG lengths resulting in an
increased percentage of EM48 nuclei with inclusions (and
higher when compared with HdhQ111/?B6J mice with similar
CAG repeat length) (Fig. 6c).
DARPP-32 levels in striatial medium spiny neurons
The striatum is critically affected in HD patients, where
there is a selective and progressive loss of MSNs (Von-
sattel and DiFiglia 1998; Vonsattel et al. 1985). DARPP-
32, a dopamine D1 receptor-activated molecule that regu-
lates phosphatase and kinase activity, is a marker of these
striatal neurons. Levels of DARPP-32 were substantially
reduced in the striatal MSNs of multiple HD mouse models
(Bibb et al. 2000; Hickey et al. 2008; Slow et al. 2003; van
Dellen et al. 2000). To assess whether the Htt CAG
mutation may produce this abnormal DARPP-32
Fig. 6 HdhQ111/?B6J.AJ10 mice showed a mild increase of neuronal
intranuclear inclusions when compared to HdhQ111/?B6J mice.
a Micrographs of striata stained with EM48 and counterstained with
thionine of representative 5 months mice with Hdh?/?B6J, HdhQ111/
?B6J (139 CAGs), Hdh?/?B6J.AJ10 and HdhQ111/?B6J.AJ10 (140
CAGs) genotypes. b Quantification of the percentage of EM48-
positive cells containing an inclusion (line represents mean of values
for each genotype) and c its correlation with constitutive Htt CAG
repeat size (the best fit linear regression line of inclusion/EM48 nuclei
by CAG repeat size for HdhQ111/?B6J is represent with solid line and
for HdhQ111/?B6J.AJ10 with the thinner solid line). HdhQ111/?B6J
(n = 9) mice are represented in squares and HdhQ111/?B6J.AJ10
(n = 9) mice in triangles. Each individual value represents the mean
observed on three consecutive striatal sections for each mouse
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phenotype on a B6J background, we immunostained stri-
atal sections of 5 months of age mice with DARPP-32
antibody (Fig. 7a). DARPP-32 immunoreactivity was sig-
nificantly reduced (p \ 0.0001) in the striatum (and
nucleus accumbens) of HdhQ111/?B6J (134.2 ± 7.1) by
14 % when compared with Hdh?/?B6J control littermates
(156.0 ± 3.7) (Fig. 7b). A similar, though milder, decrease
was observed in mice carrying one copy of the AJ chr10,
with HdhQ111/?B6J.AJ10 (137.4 ± 3.7) mice showing a
9 % reduction (p = 0.0003) when compared with control
littermates (150.7 ± 7.0). However, we did not find any
significant effect of the chr10 background in the levels of
DARPP-32 when comparing B6J with B6J.10 mice, for
both wild type (p = 0.0920) and mutant (p = 0.2521) Htt
genotypes. It should be noted, however, that Hdh?/
?B6J.AJ10 showed a 3.5 % decrease of DARPP-32
levels when compared with wild type B6J mice so that the
similar DARPP-32 immunoreactivity signal in HdhQ111/
?B6J.AJ10 and HdhQ111/?B6J striatal sections may reflect
a slower rate of decrease in DARPP-32 staining in the
former than the latter genotype.
Discussion
The length of the HTT CAG repeat is the critical deter-
minant of HD pathogenesis. However, the wide variability
in the particular symptoms that present at diagnosis, and
their timing, provide evidence that the CAG-initiated dis-
ease process can be modified. The historical candidate gene
approach to identifying modifier loci, where genes in
pathways thought to be involved in HD pathogenesis are
individually tested for an effect on AO, has produced
inconsistent findings and is being overtaken by unbiased
methods that can test millions of human genetic variants
across the entire genome in cohorts of HD subjects.
Linkage studies have identified possible chromosomal
regions containing modifier genes, including a confirmed
large interval on chromosome 6q (Gayan et al. 2008; Li
et al. 2003, 2006) and genome wide association studies to
detect effects of modifiers of motor onset in HD subjects
are ongoing. The success of genome wide approaches make
the development of strategies that can efficiently triage
variants and genes located within an implicated region to
find the one (or two) that are responsible for the modifying
effect a high priority. A functional in vivo approach that
could disclose a modifier of the CAG-disease process,
including gene variants whose effects may only be evident
in presence of the HD mutation, would provide a powerful
complement to other discovery methods in studies with HD
subjects, from natural history studies and with the advent of
induced pluripotent stems cell technologies, in cell culture
(The HD iPSC Consortium 2012).
We set a high bar in exploring a novel approach with
CSS and HdhQ111/? CAG repeat knock-in mice in a range-
finding study that utilised variants on murine chr10 synteny
to evaluate the human 6q23–24 HD modifier linkage
region. In modest cohorts of mice, we tested, simulta-
neously, whether any of the thousands of B6J versus AJ
chr10 variants, including 19 coding non-synonymous
Fig. 7 HdhQ111/? knock-in mice showed a dramatic decrease of
DARPP-32 immunoreactivity when compared to wild type mice.
a Micrographs of DARPP-32 positive cells in the striata and nucleus
accumbens of representative 5 months mice with Hdh?/?B6J,
HdhQ111/?B6J (142 CAGs), Hdh?/?B6J.AJ10 and HdhQ111/
?B6J.AJ10 (140 CAGs) genotypes. b Quantification of DARPP-32
intensity (arbitrary values ranging from 0 to 255). The mice used for
the DARPP32 analysis are as follows: Hdh?/?B6J (n = 8), HdhQ111/
?B6J (n = 9), Hdh?/?B6J.AJ10 (n = 6) and HdhQ111/?B6J.AJ10
(n = 9). Each individual value represents the mean observed on three
consecutive striatal sections for each mouse. Line represents mean of
values for each genotype. ****p \ 0.0001 and ***p \ 0.001
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SNPs, most likely to have functional impact, located in 12
homologues of human genes in the linkage region
(Mthfd1l, 1700052N19Rik, Katna1, Sash1, Samd5, Epm2a,
Utrn, Stx11, Hivep2, Nhsl1, Tnfaip3, Ifngr1), may act as
dominant modifiers (of strong effect) of early outcomes of
the dominant CAG expansion-dependent disease process in
heterozygous of HdhQ111/? mice. We selected disease
phenotypes shown to be modifiable by genetic background
(B6 vs 129) (Lloret et al. 2006) and minimised extraneous
factors by generating two sets of F1 HdhQ111 knock-in mice
with identical CAG repeat lengths (*141/142 ± 3 CAGs)
and genetic background (B6J), except for the chr10 in the
B6J.AJ10 mice that carried one chromosome from the AJ
strain.
Dominant functional chr10A/J variants, whose effects
did not require the presence of the Htt CAG repeat allele to
be observed, were segregating in our F1 progeny. We
replicated a previously reported metabolic effect of chr10A/J
variants in moderating the rapid B6J weight gain associ-
ated with an A/J obesity-resistance QTL at chr10 (Burrage
et al. 2010; Singer et al. 2004), though those mice were on
highfat diet and ours were on regular chow. However, in
the cohorts of HdhQ111/? mice analyzed we did not observe
dominant chr10A/J modifiers of CAG-dependent pheno-
types that were as strong as the variant/s responsible for
dampening the rate of weight gain. Our results, therefore,
do not provide overwhelming independent validation of
the modifier region implicated by the 6q23–24 linkage
peak.
There are several possible reasons that clearly statis-
tically significant modifying effects on HdhQ111 CAG
repeat phenotypes may not have emerged from our study.
The first is cohort size. Our study design attempted to
minimise extraneous factors by generating all F1 animals
for the study at once from the same parents but post-
mortem the F1 progeny were assigned to one of two
groups for efficient phenotyping in each of the two gen-
eral assay formats (CAG instability and immunohisto-
chemistry). Therefore, the cohorts for the CAG-dependent
phenotypes (n = 10) were half the size of the cohorts
assessed for body weight. Based on our current data, we
would need at least 19 mice per group to detect the small
effect of the chr10A/J variants in the traits approaching
significance at 5 months of age (somatic instability in the
liver and intranuclear inclusions), perhaps fewer at a more
advanced age where each phenotype is more robustly
detected (Wheeler et al. 2002). Second, the gene(s) with
the modifying effects revealed by linkage in HD subjects
may not be captured by the natural chr10 variation that
distinguishes the AJ and B6J strains, or if the true mod-
ifier has been tested in our study then its effects in HD
subjects may be unrelated to early outcomes of the CAG
expansion that we monitored in HdhQ111 mice. On the
other hand, our findings provide suggestive (though not
statistically significant) evidence for modifying effects of
chr10 variants on some of the HdhQ111 CAG disease
phenotypes, in particular those involved in liver somatic
CAG repeat instability and striatal neuron nuclear-
aggregate formation. Indeed, we found that the different
genetic background does not seem to have an effect on
striatal instability but the AJ chr10 might have a mild
detrimental effect on the levels and pattern of repeat
instability in the liver, as the same trend was observed in
all traits analyzed for this tissue (instability index, dis-
tance to the longest peak and to the second mode).
Moreover, even though the effect of the AJ chr10 on
striatum CAG instability was not statistically significant,
the HdhQ111/?B6J.AJ10 mice seemed to have a slightly
higher number of neuronal inclusions than HdhQ111/?B6J,
despite similar levels of neuronal change in the striatum
(DARPP-32 levels). An improved high-resolution quan-
titative method for detecting EM48-aggregation foci may be
required to better assess the impact of modifiers of this
phenotype. It is noteworthy that the reduction of DARPP-32
levels from wild type to Htt mutant mice was not as
accentuated in HdhQ111/?B6J.AJ10 as the observed for
HdhQ111/?B6J, suggesting that the effect of the Htt CAG
mutation in decreasing the DARPP-32 stain intensity is
greater than the effect of the difference in genetic back-
ground (of a single copy of chr10) on this phenotype.
Indeed, supporting this interpretation, Htt CAG alleles of
about 140 repeats (comparable to the mean CAG size of our
DARPP32 cohort) dramatically decrease Ppp1r1b (alias
Darpp32; ENSMUSG00000061718) mRNA levels in
6-month heterozygote B6J Htt knock-in mouse striatum,
compared to wild-type littermates (t test, p = 0.000059), as
revealed by inspection of summary whole genome RNA
sequencing data from a B6J Htt CAG repeat knock-in mouse
allelic series available from the CHDI Foundation website
(http://chdifoundation.org/datasets/).
These trends, therefore, suggest that chr10 variants may
modify some CAG-associated phenotypes but with effect
sizes too small to be reliably detected at the ages and
cohort sizes that we utilised. If the trends that we have
observed do reflect true modification, with cohorts of suf-
ficient size and age, validation and fine-structure mapping
of potential QTL(s) at chr10 could be achieved by using
sub-strain chr10 consomic mice with the region syntenous
to 6q23–24. In general, therefore, this unbiased cross-spe-
cies CCS mouse strain approach may offer an efficient
in vivo route to prioritise (conserved) genes within chro-
mosome regions that contain dominant modifier loci of
relatively strong effect that conform to the genetic criteria
of the HTT CAG repeat mechanism in HD subjects
(dominant, CAG length dependent and with striatal
specificity).
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